GSK (LON:GSK) Receives Sector perform Rating from Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their sector perform rating on shares of GSK (LON:GSK) in a report published on Tuesday,Digital Look reports. The firm currently has a GBX 1,975 price target on the stock.

Several other research firms have also issued reports on GSK. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research report on Wednesday, September 2nd. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a research note on Wednesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, GSK presently has an average rating of “Hold” and an average target price of GBX 2,039.38.

GSK Stock Up 0.3%

Shares of LON:GSK opened at GBX 1,801.50 on Tuesday. The stock has a fifty day simple moving average of GBX 1,913.92 and a two-hundred day simple moving average of GBX 1,975.65. The stock has a market capitalization of £72.19 billion, a price-to-earnings ratio of 15.29, a PEG ratio of 1.24 and a beta of 0.29. GSK has a 12-month low of GBX 1,455 and a 12-month high of GBX 2,282. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36.

GSK (LON:GSK) last released its earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, research analysts anticipate that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Buying and Selling at GSK

In other GSK news, insider Jeannie Lee purchased 802 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was purchased at an average price of GBX 5,069 per share, for a total transaction of £40,653.38. Also, insider Jonathan Symonds purchased 1,550 shares of the firm’s stock in a transaction dated Friday, June 19th. The stock was acquired at an average price of GBX 1,935 per share, with a total value of £29,992.50. In the last three months, insiders have acquired 3,618 shares of company stock worth $13,481,942. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.